{"nctId":"NCT03512197","briefTitle":"A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)","startDateStruct":{"date":"2018-07-20","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia (AML)"],"count":511,"armGroups":[{"label":"Midostaurin + chemotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Midostaurin","Drug: Chemotherapy"]},{"label":"Placebo + chemotherapy","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Chemotherapy"]}],"interventions":[{"name":"Midostaurin","otherNames":["PKC412"]},{"name":"Placebo","otherNames":[]},{"name":"Chemotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Diagnosis of AML (≥20% blasts in the bone marrow based on WHO 2016 classification). Patients with APL with PML-RARA are not eligible.\n2. Suitability for intensive induction chemotherapy in the judgment of the investigator\n3. Documented absence of an ITD and TKD activating mutation at codons D835 and I836 in the FLT3 gene, as determined by analysis in a Novartis designated laboratory using a validated clinical trial assay with clinical cutoff of 0.05 mutant to wild type signal ratio\n4. Age ≥18 years\n5. Laboratory values that indicate adequate organ function assessed locally at the screening visit\n\nExclusion Criteria:\n\n1. Central nervous system (CNS) leukemia\n2. Therapy-related secondary AML\n3. Isolated extramedullary leukemia\n4. Prior therapy for leukemia or myelodysplasia\n5. AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g., azacytidine or decitabine)\n6. Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event Free Survival (EFS)","description":"EFS was defined as the time from randomization to failure to obtain a complete remission (CR) or Complete remission with incomplete hematologic recovery (CRi) with adequate blood count recovery in induction, relapse after CR or CRi with adequate blood count recovery or death due to any cause, whichever occurred first as assessed by the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.98","spread":null},{"groupId":"OG001","value":"5.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) (Key Secondary)","description":"OS was defined as the time from randomization to date of death due to any cause. Patients entered the survival follow-up phase once they completed the safety follow up period (30 days after the last dose of midostaurin/placebo) in case of induction failure or if they had relapsed during post-treatment follow-up. Patients were then contacted by telephone every 3 months +/- 2 weeks or had a visit to follow up on their survival status, per Kaplan-Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"19.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Hematological Recovery (CRi) But With Adequate Blood Count Recovery Rate.","description":"Assessment was based on the International Working Group (IWG) criteria for AML as per investigator assessment.\n\nCR: Bone marrow: \\< 5% blasts no blasts with Auer rods; Peripheral blood: neutrophils ≥ 1.0 x 109/L platelets ≥ 100 x 109/L, no blasts; No evidence of extramedullary disease (such as central nervous system (CNS) or soft tissue involvement); Transfusion independent.\n\nCRi with adequate blood count recovery is defined as the following:\n\nBone marrow \\< 5% blasts no blasts with Auer rods Peripheral blood Neutrophils \\>= 1.0 x 109/L and 50 x 109/L \\<=platelets \\< 100 x 109/L no blasts No evidence of extramedullary disease (such as CNS or soft tissue involvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"61.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Minimal Residual Disease (MRD) Negative Status","description":"MRD- rate was defined as the rate of participants reaching MRD at any timepoint. Participants with leukemic blasts below 0.1% were considered as MRD-negative based on leukemia-associated immunophenotype (LAIP).\n\nMRD was derived from bone marrow and blood data using cellular and molecular technologies and MRD status was measured using the flow cytometry assessments for LAIP irrespective of the investigator's overall clinical response assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Minimal Residual Disease (MRD) Negative Status During Post-consolidation Phase","description":"MRD- rate was defined as the rate of participants reaching MRD at any timepoint during Post-consolidation phase. Participants with leukemic blasts below 0.1% were considered as MRD-negative based on leukemia-associated immunophenotype (LAIP).\n\nMRD was derived from bone marrow and blood data using cellular and molecular technologies and MRD status was measured using the flow cytometry assessments for LAIP irrespective of the investigator's overall clinical response assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Measurable Residual Disease (MRD) Negativity by Flow Cytometry","description":"Time to MRD- is defined as time from randomization to first occurrence of MRD-. Participants with leukemic blasts below 0.1% were considered as MRD-negative based on leukemia-associated immunophenotype (LAIP).\n\nMRD was derived from bone marrow and blood data using cellular and molecular technologies and MRD status was measured using the flow cytometry assessments for LAIP irrespective of the investigator's overall clinical response assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":null},{"groupId":"OG001","value":"2.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival (DFS)","description":"DFS as measured from the date of first CR or CRi with adequate blood count recovery to relapse or death due to any cause, whichever occurred first. Participants who did not relapse nor die were censored at the last adequate response assessment. Assessment was based on the IWG criteria for AML as per investigator assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Relapse (CIR)","description":"Cumulative Incidence of Relapse (CIR) was defined for participants with CR or CRi with adequate blood count recovery and was the time from achieving the CR or CRi with adequate blood count recovery until the onset of relapse from CR or CRi with adequate blood recovery. Participants without relapse were censored at the last adequate response assessment. Participants who died without relapse were counted as a competing cause of failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Death (CID)","description":"Cumulative Incidence of Death (CID) was defined for all participants achieving CR or CRi with adequate blood count recovery measured from the date of achievement of CR or CRi until the date of death due to any reason. Participants not known to have died were censored on the last contact date. Participants who experienced relapse were counted as a competing cause of failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to CR or CRi With Adequate Blood Count Recovery","description":"Time to CR or CRi with adequate blood count recovery was defined as the time from randomization to CR or CRi with adequate blood count recovery whichever occurred first","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":null},{"groupId":"OG001","value":"1.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Partial and Full Neutrophil Recovery","description":"The time to neutrophil recovery was assessed for the following criteria: Partial neutrophil recovery: Number of days from start of treatment to the first day neutrophils ≥0.5 x 10\\^9/L.\n\nFull neutrophil recovery: Number of days from start of treatment to the first day neutrophils ≥1.0 x 10\\^9/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Partial and Full Platelet Recovery","description":"Time to platelet recovery was assessed for the following criteria: Partial platelet recovery: Number of days from start of treatment to the first day platelets ≥50 x 10\\^9/L.\n\nFull platelet recovery: Number of days from start of treatment to the first day platelets ≥100 x 10\\^9/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.953","spread":null},{"groupId":"OG001","value":"0.887","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentrations for Midostaurin and Its Metabolites: CGP52421 and CGP62221 for Non-poor Metabolizers","description":"Serial pharmacokinetics (PK) samples were collected in Non-poor metabolizer participants to assess the plasma concentrations of midostaurin, CGP52421 and CGP62221.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1110","spread":"791"},{"groupId":"OG001","value":"30.0","spread":"35.4"},{"groupId":"OG002","value":"37.6","spread":"45.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2000","spread":"897"},{"groupId":"OG001","value":"80.6","spread":"48.8"},{"groupId":"OG002","value":"198","spread":"178"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1370","spread":"448"},{"groupId":"OG001","value":"92.1","spread":"47.1"},{"groupId":"OG002","value":"285","spread":"222"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1090","spread":"365"},{"groupId":"OG001","value":"79.3","spread":"31.4"},{"groupId":"OG002","value":"280","spread":"196"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5340","spread":"3190"},{"groupId":"OG001","value":"417","spread":"162"},{"groupId":"OG002","value":"1470","spread":"812"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6840","spread":"3480"},{"groupId":"OG001","value":"451","spread":"157"},{"groupId":"OG002","value":"1520","spread":"777"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4800","spread":"2860"},{"groupId":"OG001","value":"430","spread":"167"},{"groupId":"OG002","value":"1590","spread":"732"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8330","spread":"5300"},{"groupId":"OG001","value":"776","spread":"261"},{"groupId":"OG002","value":"3030","spread":"1460"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7010","spread":"4260"},{"groupId":"OG001","value":"828","spread":"229"},{"groupId":"OG002","value":"3170","spread":"1310"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6520","spread":"5230"},{"groupId":"OG001","value":"1090","spread":"304"},{"groupId":"OG002","value":"4070","spread":"1400"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5960","spread":"4040"},{"groupId":"OG001","value":"1050","spread":"332"},{"groupId":"OG002","value":"3990","spread":"1580"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6190","spread":"4880"},{"groupId":"OG001","value":"1310","spread":"467"},{"groupId":"OG002","value":"4540","spread":"1950"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6740","spread":"4390"},{"groupId":"OG001","value":"1240","spread":"380"},{"groupId":"OG002","value":"4100","spread":"1680"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5990","spread":"4460"},{"groupId":"OG001","value":"1220","spread":"336"},{"groupId":"OG002","value":"4320","spread":"1660"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":"128"},{"groupId":"OG001","value":"922","spread":"246"},{"groupId":"OG002","value":"269","spread":"390"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1110","spread":"660"},{"groupId":"OG001","value":"1090","spread":"409"},{"groupId":"OG002","value":"615","spread":"601"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":"264"},{"groupId":"OG001","value":"1060","spread":"49.5"},{"groupId":"OG002","value":"376","spread":"531"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1630","spread":"780"},{"groupId":"OG001","value":"1860","spread":"387"},{"groupId":"OG002","value":"1890","spread":"608"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2580","spread":"1430"},{"groupId":"OG001","value":"1620","spread":"505"},{"groupId":"OG002","value":"2030","spread":"677"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1950","spread":"1630"},{"groupId":"OG001","value":"1710","spread":"500"},{"groupId":"OG002","value":"1990","spread":"746"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":"126"},{"groupId":"OG001","value":"968","spread":"469"},{"groupId":"OG002","value":"274","spread":"289"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1030","spread":"522"},{"groupId":"OG001","value":"983","spread":"465"},{"groupId":"OG002","value":"437","spread":"250"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"14.9"},{"groupId":"OG001","value":"996","spread":"105"},{"groupId":"OG002","value":"44.1","spread":"41.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1810","spread":"1470"},{"groupId":"OG001","value":"1460","spread":"522"},{"groupId":"OG002","value":"1750","spread":"995"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2620","spread":"1230"},{"groupId":"OG001","value":"1720","spread":"640"},{"groupId":"OG002","value":"2140","spread":"1120"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2430","spread":"2450"},{"groupId":"OG001","value":"1570","spread":"644"},{"groupId":"OG002","value":"1960","spread":"1030"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"472","spread":"407"},{"groupId":"OG001","value":"1470","spread":"148"},{"groupId":"OG002","value":"786","spread":"487"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"309","spread":"0"},{"groupId":"OG001","value":"1010","spread":"0"},{"groupId":"OG002","value":"887","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"496","spread":"288"},{"groupId":"OG001","value":"1070","spread":"396"},{"groupId":"OG002","value":"951","spread":"650"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"748","spread":"136"},{"groupId":"OG001","value":"1180","spread":"458"},{"groupId":"OG002","value":"857","spread":"119"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"419","spread":"4.95"},{"groupId":"OG001","value":"803","spread":"30.4"},{"groupId":"OG002","value":"784","spread":"142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"311","spread":"0"},{"groupId":"OG001","value":"1120","spread":"0"},{"groupId":"OG002","value":"896","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"639","spread":"174"},{"groupId":"OG001","value":"960","spread":"180"},{"groupId":"OG002","value":"962","spread":"344"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"408","spread":"0"},{"groupId":"OG001","value":"1020","spread":"0"},{"groupId":"OG002","value":"1050","spread":"0"}]}]}]},{"type":"SECONDARY","title":"AUC0-t: Pharmacokinetic (PK) Parameter for Midostaurin and Its Metabolites: CGP52421 and CGP62221 at Cycle 1, Day 8","description":"The AUC from time zero to a measurable concentration sampling time (t) (mass x time x volume-1). Note: as the last sampling time was at 12 h, AUC0-12h was determined after the first dose, reported at Cycle 1, Day 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14800","spread":"37.5"},{"groupId":"OG001","value":"712","spread":"78.4"},{"groupId":"OG002","value":"1830","spread":"135"}]}]}]},{"type":"SECONDARY","title":"AUClast: Pharmacokinetic (PK) Parameter for Midostaurin and Its Metabolites: CGP52421 and CGP62221 at Cycle 1, Day 8","description":"The AUC from time zero to the last measurable concentration sampling time after the first dose reported at Cycle 1, Day 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12200","spread":"59.6"},{"groupId":"OG001","value":"493","spread":"139"},{"groupId":"OG002","value":"1130","spread":"249"}]}]}]},{"type":"SECONDARY","title":"Cmax: Pharmacokinetic (PK) Parameter for Midostaurin and Its Metabolites: CGP52421 and CGP62221 at Cycle 1, Day 8","description":"The maximum (peak) observed plasma drug concentration after the first dose administration reported at Cycle 1, Day 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1910","spread":"37.8"},{"groupId":"OG001","value":"74.7","spread":"72.3"},{"groupId":"OG002","value":"183","spread":"128"}]}]}]},{"type":"SECONDARY","title":"Tmax: Pharmacokinetic (PK) Parameter for Midostaurin and Its Metabolites: CGP52421 and CGP62221 at Cycle 1, Day 8","description":"The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration reported at Cycle 1, Day 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":"101"},{"groupId":"OG001","value":"5.38","spread":"89.9"},{"groupId":"OG002","value":"7.17","spread":"57.8"}]}]}]},{"type":"SECONDARY","title":"Total Score for Each Time Point for the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu)","description":"The total FACT-Leu score consists of 44 items with total scores ranging from 0 to 176. Higher scores indicate better health-related quality of life ( HRQoL). Negative changes from baseline indicate a worsening of HRQoL while positive changes indicate an improvement in HRQoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.8","spread":"22.64"},{"groupId":"OG001","value":"123.1","spread":"21.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.9","spread":"21.50"},{"groupId":"OG001","value":"122.1","spread":"19.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124.8","spread":"20.34"},{"groupId":"OG001","value":"123.5","spread":"20.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.0","spread":"25.09"},{"groupId":"OG001","value":"119.8","spread":"18.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135.9","spread":"17.67"},{"groupId":"OG001","value":"136.9","spread":"21.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.7","spread":"21.45"},{"groupId":"OG001","value":"140.1","spread":"21.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136.4","spread":"22.87"},{"groupId":"OG001","value":"139.2","spread":"25.00"}]}]}]},{"type":"SECONDARY","title":"Scores for Each Time Point for the EQ5D-5L (a Visual Analogue Scale (VAS))","description":"The EQ5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The patient is asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The questionnaire also included a Visual Analogue Scale (VAS), where the patient is asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":"22.98"},{"groupId":"OG001","value":"64.3","spread":"22.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":"20.95"},{"groupId":"OG001","value":"64.4","spread":"21.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":"21.02"},{"groupId":"OG001","value":"64.0","spread":"21.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.9","spread":"21.03"},{"groupId":"OG001","value":"65.2","spread":"20.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":"15.42"},{"groupId":"OG001","value":"76.2","spread":"16.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":"15.00"},{"groupId":"OG001","value":"77.3","spread":"14.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","spread":"20.08"},{"groupId":"OG001","value":"73.4","spread":"1972"}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"On-treatment deaths were collected from start of treatment (FPFT) up to 30 days after study drug discontinuation, for a maximum duration of approx. 18 months.\n\nRandomized but not treated deaths were collected after randomization but before treatment with study drug.\n\nPost-treatment survival follow-up deaths were collected after the on-treatment period up to approx. 18 months. Participants who did not die during the on-treatment period and had not stopped study participation at the time of data cut-off (when study was terminated) were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":95,"n":245},"commonTop":["Pyrexia","Nausea","Diarrhoea","Febrile neutropenia","Hypokalaemia"]}}}